About 68 results

ALLMedicine™ Acute Angioedema Center

Research & Reviews  22 results

Angioedema: differential diagnosis and acute management.
Postgraduate Medicine; Tachdjian R, Johnston DT

Jun 18th, 2021 - A clinical vignette illustrates a typical presentation of a patient seeking help for acute angioedema. Despite the risks of SARS-CoV-2 (COVID-19) exposure, it is critical to evaluate patients with acute angioedema in person, because there is alway...

Pediatric Emergency Department Management of C1 Inhibitor Deficiency.
Pediatric Emergency Care; García Sánchez P, Plata Gallardo M et. al.

May 20th, 2021 - C1 inhibitor deficiency is a rare, potentially life-threatening syndrome. Acute attacks of angioedema may occur at any time, so the emergency department (ED) constitutes an indispensable component of its care. To describe the reasons for consultat...

Life-Threatening Acute Angioedema, a Rare Complication After Secondary Blepharoplasty.
Aesthetic Surgery Journal; Berenguer B, García T et. al.

Apr 1st, 2021 - Life-Threatening Acute Angioedema, a Rare Complication After Secondary Blepharoplasty.|2021|Berenguer B,García T,San Basilio M,|

Significant predictive factors of the severity and outcomes of the first attack of acut...
BMC Pediatrics; Syue YJ, Li CJ et. al.

Nov 12th, 2019 - The initial episode of angioedema in children can be potential life-threatening due to the lack of prompt identification and treatment. We aimed to analyze the factors predicting the severity and outcomes of the first attack of acute angioedema in...

An 82-year-old man with recurrent angioedema.
Allergy and Asthma Proceedings; Schuler CF, Pedersen EA et. al.

Sep 14th, 2019 - Angioedema is a potentially life-threatening swelling condition that can occur either in isolation or in the context of other syndromes, e.g., anaphylaxis. Angioedema is typically asymmetric, lasts for hours to days, is not gravity dependent, and ...

see more →

Clinicaltrials.gov  3 results

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Apr 16th, 2019 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Oct 9th, 2018 - This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Aug 7th, 2015 - HAE is characterized by recurrent localized angioedema caused by uncontrolled activation of the complement and contact systems due to a congenital deficiency of functional C1 inhibitor. rhC1INH has been developed to offer a more widely available t...

see more →

News  2 results

FDA approves C1-esterase inhibitor for hereditary angioedema
Elizabeth Mechcatie

Jul 17th, 2014 - Ruconest, an injectable human recombinant C1-esterase inhibitor, has been approved by the Food and Drug Administration for treating acute angioedema attacks in adults and adolescents with hereditary angioedema. Ruconest is the first recombinant C1.

Study Finds Icatibant Relieves Acute Angioedema
Family Practice News;

Apr 8th, 2011 - Because many of the adverse events that were most commonly reported are associated with hereditary angioedema, "we could not separate whether this was due to drug effect or due to the attack," Dr. Lumry said.

see more →